The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An open-labeled, multicentric clinical study of cetuximab combined with intensity-modulated radiotherapy (IMRT) plus concurrent chemotherapy in locoregionally advanced (LA) nasopharyngeal carcinoma (NPC): A 2-year follow-up report.
Chun-yan Chen
No relevant relationships to disclose
Chong Zhao
No relevant relationships to disclose
Li Gao
No relevant relationships to disclose
Jin-yi Lang
No relevant relationships to disclose
Jian-ji Pan
No relevant relationships to disclose
Chao-su Hu
No relevant relationships to disclose
Feng Jin
No relevant relationships to disclose
Ren-sheng Wang
No relevant relationships to disclose
Conghua Xie
No relevant relationships to disclose
Tongyu Lin
No relevant relationships to disclose
Tai-xiang Lu
No relevant relationships to disclose